SecurityABBV / AbbVie Inc.
InstitutionAchmea Investment Management B.V.
Shares286,085
Value $ 26,502,000
Related EPA:ABBV / AbbVie Inc.

Achmea Investment Management B.V. reports 18.21% increase in ownership of ABBV / AbbVie Inc.

July 27, 2018 - Achmea Investment Management B.V. has filed a 13F-HR form disclosing ownership of 286,085 shares of AbbVie Inc. (NYSE:ABBV) with total holdings valued at $26,502,000 USD as of June 30, 2018. Achmea Investment Management B.V. had filed a previous 13F-HR on May 15, 2018 disclosing 242,010 shares of AbbVie Inc. at a value of $22,904,000 USD. This represents a change in shares of 18.21 percent and a change in value of 15.71 percent during the quarter.

Other investors with positions similar to Achmea Investment Management B.V. include Manning & Napier Group, Llc, Creative Planning, Herndon Capital Management Llc, Public Employees Retirement Association Of Colorado, Northwestern Mutual Investment Management Company, Llc, and Destination Wealth Management.

AbbVie Inc. has declared a standard industrial code (sic) of 2834 which is the "Pharmaceutical Preparations" industry. Achmea Investment Management B.V.'s top industries are "Automotive Repair, Services, And Parking" (sic 75), "Printing, Publishing, And Allied Industries" (sic 27), and "Textile Mill Products" (sic 22).

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR AbbVie ABBV US 00287Y109 93.64 286,085 18.21 26,502 15.71 4,127 -529 -2.31
2018-03-31 13F-HR AbbVie ABBV US 00287Y109 95.67 242,010 -5.84 22,904 -7.85 -1,437 -513 -2.06
2017-12-31 13F-HR AbbVie ABBV US 00287Y109 92.76 257,033 121.25 24,854 140.83 13,067 1,467 14.22
2017-09-30 13F-HR AbbVie ABBV US 00287Y109 80.66 116,173 1.41 10,320 24.28 131 1,885 22.70
2017-06-30 13F-HR/A-1 AbbVie ABBV US 00287Y109 68.82 114,553 -5.10 8,304 5.58 -424 863 10.97
2017-03-31 13F-HR/A-1 AbbVie ABBV US 00287Y109 65.16 120,709 0.00 7,865 0.00 0 0 0.00
2017-03-31 13F-HR AbbVie ABBV US 00287Y109 120,709 7,865

Related SEC Filings

ABBV / AbbVie Inc. / Capital Research Global Investors - SC 13G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* AbbVie Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00287Y109 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shal

ABBV / AbbVie Inc. / Capital Research Global Investors - SC 13G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* AbbVie Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00287Y109 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shal

ABBV / AbbVie Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-08 sec.gov
abbvieinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 4 )*       Name of issuer:  AbbVie Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  00287Y109     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule 13d-1(b)   ( 

ABBV / AbbVie Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-08 sec.gov
abbvieinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 4 )*       Name of issuer:  AbbVie Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  00287Y109     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule 13d-1(b)   ( 

ABBV / AbbVie Inc. / BlackRock Inc. - 3G/A (Passive Investment)

2018-02-08 sec.gov
us00287y1091_012418.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) ABBVIE INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 00287Y109 -------------------------------------------------------- (CUSIP Number) December 31, 2017 -------------------------------------------------------- (D

Related News Stories

AbbVie CFO Chase to retire by mid-year 2019

2018-10-19 reuters
(Reuters) - AbbVie Inc (ABBV.N) said on Friday that William Chase stepped down as chief financial officer and will retire from the company in mid-2019, and the U.S. drugmaker promoted controller, Robert Michael, to the CFO role. (16-0)

AbbVie CFO Chase stepping down, to retire by mid-year 2019

2018-10-19 reuters
(Reuters) - AbbVie Inc (ABBV.N) said on Friday that Chief Financial Officer William Chase is retiring in mid-2019 and named its controller, Robert Michael, his immediate successor as CFO. (9-0)

AbbVie names Robert Michael chief financial officer

2018-10-19 reuters
Oct 19 (Reuters) - AbbVie Inc on Friday appointed Robert Michael as its chief financial officer, replacing William Chase, who will retire in mid-2019. (9-0)

AbbVie CFO Bill Chase to retire

2018-10-19 marketwatch
AbbVie Inc. ABBV, -0.94% disclosed Friday that Chief Financial Officer William "Bill" Chase plans to retire in mid-2019, and will be succeeded as CFO by Robert Michael effective Friday. The stock slipped 0.7% in morning trade. Chase has been appointed executive vice president of finance and administration, also effective Friday. Michael, how has been the biopharmaceutical company's controller since March 1, 2017, will continue to report to Chase. (9-0)

30 Marijuana Stocks to Buy as the Future Turns Green

2018-10-17 investorplace
When it comes to cannabis, we’ve come a long way since former President Bill Clinton denied ever inhaling. With the previous presidential administration’s frankness on the matter, marijuana has become more blasé. Naturally, marijuana stocks have also increased in popularity, where we have more choices today than was previously thought possible. (38-4)



CUSIP: 00287Y109